当前位置： SCI文献检索 > ADVANCED DRUG DELIVERY REVIEWS期刊下所有文献 > Advancement in integrin facilitated drug delivery.

Advancement in integrin facilitated drug delivery.

Abstract：

:The research of integrin-targeted anticancer agents has recorded important advancements in ingenious design of delivery systems, based either on the prodrug approach, or on nanoparticle carriers, but for now, none of these has reached a clinical stage of development. Past work in this area has been extensively reviewed by us and others. Thus, the purpose and scope of the present review is to survey the advancement reported in the last 3years, with focus on innovative delivery systems that appear to afford openings for future developments. These systems exploit the labelling with conventional and novel integrin ligands for targeting the interface of cancer cells and of endothelial cells involved in cancer angiogenesis, with the proteins of the extracellular matrix, in the circulation, in tissues, and in tumour stroma, as the site of progression and metastatic evolution of the disease. Furthermore, these systems implement the expertise in the development of nanomedicines to the purpose of achieving preferential biodistribution and uptake in cancer tissues, internalisation in cancer cells, and release of the transported drugs at intracellular sites. The assessment of the value of controlling these factors, and their combination, for future developments requires support of biological testing in appropriate mechanistic models, but also imperatively demand confirmation in therapeutically relevant in vivo models for biodistribution, efficacy, and lack of off-target effects. Thus, among many studies, we have tried to point out the results supported by relevant in vivo studies, and we have emphasised in specific sections those addressing the medical needs of drug delivery to brain tumours, as well as the delivery of oligonucleotides modulating gene-dependent pathological mechanism. The latter could constitute the basis of a promising third branch in the therapeutic armamentarium against cancer, in addition to antibody-based agents and to cytotoxic agents.

journal_name

Adv Drug Deliv Rev

journal_title

Advanced drug delivery reviews

authors

Arosio D,Casagrande C

doi

10.1016/j.addr.2015.12.001

subject

Has Abstract

pub_date

2016-02-01 00:00:00

pages

111-43

eissn

0169-409X

issn

1872-8294

pii

S0169-409X(15)00286-0

journal_volume

pub_type

杂志文章,评审

在线工具

Advancement in integrin facilitated drug delivery.